Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody ...

Todd Wiseman was getting anxious. The Olathe, Kansas–based musician and construction worker had been through 18 weeks of chemotherapy to manage his diffuse large B-cell lymphoma (DLBCL) only to have ...

Explore effective operational protocols for managing oncology patients, emphasizing multidisciplinary teamwork and proactive strategies to handle treatment toxicities. Successfully implementing ...

HOUSTON -- More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a ...

From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

Lunsumio VELO targets CD20 on lymphoma cells and lymphocytes, enhancing immune response against cancer cells. The subcutaneous version offers a one-minute administration, reducing clinic time and side ...

Immunotherapy uses the power of your immune system to fight your cancer. There are several types of immunotherapies. They include antibody therapies and CAR T-cell therapy. Immunotherapies are among ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for patients with previously untreated follicular lymphoma with a high tumor ...

Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...

Lunsumio VELO, a subcutaneous CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two systemic therapies. The GO29781 study reported a 75% objective response ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...